TREATMENT OUTCOMES FOR CHILDREN WITH ANXIETY DISORDERS

本申请提出Moira A. Rynn，医学博士宾夕法尼亚大学的一个以病人为导向的研究职业发展奖。 该计划的目的包括：1）支持我发展成为一名独立的研究科学家; 2）支持和加强我作为儿童和青少年焦虑症研究者的发展; 3）发展我利用我的临床经验设计和执行方案的能力，以回答提出的研究问题;以及4）根据在奖励期间进行的研究，为准备RO 1补助金申请提供基础。这些目标将通过一个结构化的四部分计划来实现：1）在Brian Strom博士的监督下完成临床流行病学科学硕士学位，这是一个正式的学术课程和教程计划，旨在提高我的研究技能; 2）获得研究培训和指导，由一位资深科学家担任我的赞助商（Karl Rickels，医学博士）。以及共同发起人（Edna Foa，Ph.D）和合作者（Elizabeth Weller，M.D.，欧文卢基博士，约翰·马奇医学博士M.P.H.布莱恩·斯特罗姆医学博士M.P.H.菲利普C。肯德尔博士，ABPP）; 3）参加情绪和焦虑障碍科正在进行的儿童和成人焦虑和抑郁的精神药理学试验; 4）设计和执行原始临床研究治疗方案。符合广泛性焦虑症、分离焦虑症或焦虑症nos诊断的8至12岁11个月的儿童将进入一项随机、双盲、安慰剂对照试验，以评估每天50 mg舍曲林的安全性和有效性（Pt N = 60）。 我还将评估父母精神病理学的存在对孩子的损伤水平、障碍发作和对药物治疗的反应的调节作用。 家庭将被跟踪一年，以收集进一步的研究。

This application proposes Moira A. Rynn, M.D. for a Mentored Patient-Oriented Research Career Development Award at the University of Pennsylvania. The aims of this program include: 1) to support my development into an independent research scientist; 2) to support and enhance my development as an investigator in anxiety disorders in children and adolescents; 3) to develop my ability to use my clinical experience to design and execute a protocol that will answer a proposed research question; and 4) to provide the groundwork for the preparation of an RO1 grant application based on the research performed during the award period. These aims will be accomplished through a structured four-part plan: 1) to complete a Master's of Science of Clinical Epidemiology, a program of formal academic courses and tutorials to enhance my research skills, under the supervision of Dr. Brian Strom; 2) to obtain research training and mentoring by a senior scientist who will serve as my sponsor (Karl Rickels, M.D.) as well as by a co-sponsor (Edna Foa, Ph.D) and collaborators (Elizabeth Weller, M.D., Irwin Lucki, Ph.D., John March, M.D., M.P.H., Brian Strom, M.D., M.P.H., and Philip C. Kendall, Ph.D., ABPP); 3) to participate in several ongoing psychopharmacological trials for anxiety and depression in both children and adults in the Mood and Anxiety Disorders Section; and 4) to design and execute an original clinical research treatment protocol. Children aged 8 to 12 years and 11 months who meet the diagnosis of generalized anxiety disorder, separation anxiety disorder, or anxiety disorder nos will enter a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of 50 mg sertraline per day (Pt N = 60). I also will evaluate the moderating effect the presence of parental psychopathology has on the child's level of impairment, onset of disorder and response to medication treatment. Families will be followed for one year to collect for further research.